<SEC-DOCUMENT>0000000000-18-000182.txt : 20181029
<SEC-HEADER>0000000000-18-000182.hdr.sgml : 20181029
<ACCEPTANCE-DATETIME>20180103111357
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000000000-18-000182
CONFORMED SUBMISSION TYPE:	UPLOAD
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20180103

FILED FOR:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			China SXT Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001723980
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		UPLOAD

	BUSINESS ADDRESS:	
		STREET 1:		178 TAIDONG ROAD NORTH
		CITY:			TAIZHOU
		STATE:			F4
		ZIP:			225300
		BUSINESS PHONE:		8652386298290

	MAIL ADDRESS:	
		STREET 1:		178 TAIDONG ROAD NORTH
		CITY:			TAIZHOU
		STATE:			F4
		ZIP:			225300
PUBLIC REFERENCE ACCESSION NUMBER:		0001144204-17-062247
</SEC-HEADER>
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.pdf
<TEXT>
<PDF>
begin 644 filename1.pdf
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M"GB<[<&!     ,,@?^K=X 15 0
M
M
M
M
M
M
M
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M:A:A=X=D1AA7T!)B^6:!X?+SB[2+^Q'-[[I_(IW4+IJ.:MZ+]9UVC7;15]A
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MOICWS)"SM(LAC<T_2\O<LC:0U97:9-J0AU@3H[Y"N\A+LR\&2"=_!6NN:OV
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ME>>(O\]VVQ@1$1$1$1&1OQF6QNF/0(3,FC.+D&NXD\2_K--9N9_4+G)QC9A
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M*(,D.D59?!:45G$+D41=S82ATV-1U[6&ZY0 A6M%T]5I(B)<:R47K>8+E&8
MUA#Q3%B89!![ R@);2\Q)E4]\"C.'TRXU'Z#+E*U9E;!)4;N KZ)2&OT@X[V
M6$V%0U<CTBIXMF9$G5:@!,^K55AC'GBGTT!R/N8V\3[F?>/M@HZT((*)Y.QF
MB.U:PF_&><-(,09A.)BSOE8L:>2U!,*+!W:VX8JO%-^L#6Q,":,H@_M6AG!F
M('V G>2%_ >?&;N]O><5LVE[]U/Z)L?W,&B:O^U-TT\#)SQJFN.>;?)]H^JM
M7K-;E%.@6HY#[\$P/UB=ZKGT,$H&7]U _3AUXN]MH'X4.MXQ$-.SN+6*'S30
MHP&70+0!8Z4J!."4W3ACYE+@.ML9N#5\*3 -X/.E+,;J=@I<^L8@[H K&BIN
MLEE3)U&3GG;0P&A>Z[-C;+(9ZIE<[OI,&BKI(&8Q&B X0]O&C+Y_H&'!%&;S
M()I@=MVC]Y=K'FGV^;;'^B!T1R,BG:=YM!(BQ\.M,Q41^[%7P^OFOO1J"9+"
M%S1>XDX6>V[LA+US+?<]=M3S2G\;]#TPYO@8RYY[%OM6^<]AG\HJ&!RYC(:S
MK)"5@27Z,]B>J>$5R-Q*5)B:,E9;@.!%\0# LLZ%JDPI/B%J3P"]^R*CF[3W
M6%(6$'BA/X".6GZ'.&EHXLZ\I<0+Z>J$+//F?D9'DA\8[;_KZKC*T:LM9H-D
MP!YYY*#-C-^"3 ;2D8W'QM./O3,>[_9,]O&WD<$V=-YBU)_WM>Q"B?M6*N+O
M-5O5 XL_B=9"X'9BTA19P=LJ6Q\2^(D++$;=="AADR]S:O9B']H73\3V'#;3
ML _;!)J/YX03_[2&_U]9][^6!ZV6#0IE;F1S=')E86T-96YD;V)J#3,@,"!O
M8FH-/#PO0V]N=&5N=',@-" P(%(O0W)O<$)O>%LP(# @-C$R(#<Y,ETO365D
M:6%";WA;," P(#8Q,B W.3)=+U!A<F5N=" Q.2 P(%(O4F5S;W5R8V5S/#PO
M1F]N=#P\+T8Q(#(Y(# @4CX^/CXO4F]T871E(# O5'EP92]086=E/CX-96YD
M;V)J#30@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:" Q.3$W
M/CYS=')E86T-"GB<U5AM;^,V$OZ>7S$(<&@*)*RH5^MCDVX6*8K;-)OK'0[]
M0DNTS586M:(4U_=K_%-OAI1LR9:WW<V'NR1(8-*C&<[P>>9%GRXXT._3^PN/
MS6!S$:>0!!ZL+WP_88%O%\7%QPL/WD^*SH:BLX'H9DJ<^R@>\(BEL5U\1K/O
M#41][T\TQVF(XCP)Z2"T^(QFSS^(TN*,YBC GT[[+&#X&9\*4A;'_7K"QNBA
M&8N3X4-V/;3V\\6GB]MG>ZC(A^<<O[CA,_KPW3VJQ*U%I[Q>7ES!O:I-\W>Q
MEO"3<!_N9;F$?Z]T^^WS;_CP<BC=;WG@C50/1.[T6E2BW +INENI4L#'?SW#
MXTK4:Y')ME&9*,PU/)09^SH+/[:E!!Y?@^_Q!![%4D+PUS3Y?1AF?QJ%HZ??
M/6-@,:P<:(,C>B ) WA>#Z)Z-8K<4-*?D>357XC&\"EN]5_](#.YGLL: L^Y
M?"07IT[[(1!XV$\6!S[\:''1__U\=M]C283@(76)Q[R(>)*F+(G[-4&,X#6.
M09QP%D5D?G(30Y<- _2PK@ITN%&Z-* 7\*&MX58JC)HHX?+=6M9+6KRO]:99
M$9((2)?74)%KLZ'?^\.-3-T$F#5PN[^R<]X.G4!^01PEY/_X-C\;R5,]Z'<8
M,/](">>LTS.0Y1ZR=E+\L9#"2#!M515R+<M&%,46JEJ_J%Q":V"C,#"9KI2T
M <2O85.KII$E[J[7;=F']QJ$@5PN5"GS8> ZV_Z,.=2H$I[:0NY"O..VS!%F
MS4K"1YFUJ):L?)\UU[@G&MCJ]AITC7>UU<A T38K7:O_R!P:#;D&HT&7)%5/
M&.0A"ZW!N5R)8H%W6DN##N*SNTKC^1LE"E#EBS2-K@U^@EH62I29)*UX('(+
MHE^O\E^_)=<GCCEAUO.LT<U*HGQ-IR]U0\]N47TC5-D%<]=I' >1?26;_E?[
M!Q9'6(K2R-;1F 7]<IK$41*S\)C$A\UC$A-I[W1=Z5HT> 5-W69-6\LIEO;&
M1ZIN>(1E\HLY&L4^BU_-T2B<,7[,4?\L1Z?$GPDFF+\;0\ DIPW6$U'F$,9$
M P+86C39R@&*)'M!N+])'(41_!5"FIB#4J? Q9K/$D?0G+BQZ"#9(Y_V+.[%
M7+](:WTN"[VQ7^8:$T(.A2*6&I#*8O_R ]((&2LOD0:[RP^+Q819GC)7=:PD
MNX0N(]7R11GY=OD0IB'S(]NC8?>7]NMI0H1IU)6#R<UC0CPI\SO<BXSR5L<"
M'HQBV]L<:;CA7D#;7TJ$<,:)RZ\D0A@G+B$/B1"<)<*4^"T"(R=H6\PIDQ7:
M8"(8@)VGUZ :$%4E!>9T@B$B$O^:52V1&RWF>BSZQM47*;+5*23#R %29)EN
M2\+U K/X6ELMV#9P[V]$"BH[R"8LF&!$(0WKD:O*K&BQ>.(A:EW5BI)633>V
ML#<V83"@_V1RX%,MEZ+.J3EQ50++4MG4>TJB=6>6""W K*DPEZUMV_#KO:-O
MF$ (CLBUA9S%^_49 N&(Y9T0:+\Y55&J44<,\]9@]C+8!QCLAN:_=;E2E00A
M[!KH!@UCK.=;/&X.NR..#-X$F-QP^XOYYG%*%:_D6S"+74(?\BT\R[<I<2H\
M ^0B)A>6.]J!_UP$J38TW:,=TSI16S_JB>H3)'Y7!N0?E3:VP[N&S4IA4<LU
M/D4USK': AZ[U>W^'+UA-JX=^S.<)5Z 77AJK:(J=*ZPEXY/'<!0=H<@OE$>
MP8$+KS]W;6G^MDM4$/AL9ELV5RZZ]33#@@![J&.&'3:/&?:NQ*2923%7A6JV
ME)+NU(LJX"?EMA )'9,"?]3 ]4<9*;[QOZYR!;[736NO8I(7'_,H.L^C$^%_
M2D*O=%@U#98#FK/,?L2!E<"&:BYQHG*(RG?S[<Y*4P$RLCCNX$Z1[%,"LDC.
M9&VGC%L:4\P*?E$TXL*#*9"6CIN/4N.P]XV!)UFU<YR/[?785P6%V% KV5#E
MZ-G42"PMK9DPFB1NGL1I!UW!&F6P=^QJ%#FV),>06@N\\:Z0'6;'T@YC?2&]
M_>7!G>WIKO=ZPB!VY&Z(G&AI:8H]!%>0JR#_6*FYZB6HIBK3%]&],,.I;B(E
M^=B)NP'2C:M!O#LWKI(7/,4&>K=[L\G ]P-B'-([#5@<].OI9.#[(66*<3(X
M;!XG@W_@W6"('FN=29GOB3]N67NS(R4WW.>T_:7$]SGO*O%KB,_3F!TKX?%9
MZD^)]^]7$*AJL;78*>4&\KI=0H: 5SFB<) +-@K)1B\J1(U5AQB1RQ><LRJ7
M ZHNA*=PY3/?#8Y7BUJOK2&]P'*-Q&,[^+XPNN^876%$^"_MK73ZB0GV!%B
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M+?^HK!!*0U-GNO'5?X?^Q(K7MOW1Y7(-1FH_7_$);Q1#C?5F0Z4<\JK Q>A
M/O)"<WU7I0M>\_$'.,<72QR!B^;)U,A$CT]V.4T<@4M!*F/BZ&7GQ/%MHW0#
MTR=_,*Z1K;/AYGD2:>%3<]_7(]QS<]]'T^M>Y+YW-?<G]5OLHT@!@NN#@8C^
MLS[8_&=[)E< LI:_RUFY40U9L/QO##SDCNU$H\B][<6LZLNM1GZ@(471;T5V
M,0TH/]07. 94+[N8"T"HKX6LA*[SY(=<U:)M*AYJB9B!!SJLA4.L=:<8V9U3
M-$"0/AEL?N3$SP8;I2V!#\%&KX-M2O_4D.D0F'9=H;IHNL-,T/(OZ9O\99N.
MA#^*XA$@%(_<=D\5!G8,#Z@UIAQ8*CL[@!MW!6!4WP8,#+<F]IBY^PEER3/]
M(E#)'/-HI6L+TF$#+3-A"-T]FBH$4Y<^:>IW]-\;Z$>5HRAAK-Z+KH1MA'/$
MA-M.1&_!RB0PP["0.W(W]PQ.K-AYY>B?)CRBV6Y+@-E&W?G="R9V&OJ&V*D?
MZ.<ZNYS.0XJ1Y9S8>]EY'CYL]9P(^*UPW:\VDIL*V*7>:%KO70]-S<T,__0>
MCP;>\WE>OXI>\KQ_-?4F]=O4^]2P$\^OFZ(@FL/1S0!W:XY1I&('MBPPK1QZ
MFG]H_M*[P/VD*5=M!IJ(3N#1HWIF-$]39]&V.;;/X9.7QH>V@V[%-GZB/.(,
MIO?J=KS<6N(E,8(!' >Q9FR[G,:QEZ1V#)B2G>/X(_I )C/S4$+></1XHAH@
M.?1&2.Z<#XW-O3C\DB*BMYT_?3X9R5[DMIP\1')P%<F3^BV25<6S#LAYV3:]
MHC2/3F6#SAG%53,U^MURA<9$G3C>#BDK4=6V0[^$L1=$'9'_ 3-JE6=V%LC;
M6>!XLE-510X[W6!?,=W-*_O4)77G-'CMDBA;_6O7"X8WNDS]7$P]7S]BVN45
M>*,/.'\N[F67;U0U+PIT! VN$6UEQ67=/5B%HTF\]SRT-/= MU_PJ.JYZ7.1
MG0;ML\P0V.%58$^IHWX3S@ MBR +K,PR8X\VU2QW>0W<GD8[V\^T;'JH])M'
M:^(2UXG;5@;T)^B(LG[2U.51<:ZG^1/)'P='(+_?<&?CW)H952@[HX*P=PRG
MD;?Z#?8H9/N]_P!3N+G$#0IE;F1S=')E86T-96YD;V)J#3<@,"!O8FH-/#PO
M0V]N=&5N=',@." P(%(O0W)O<$)O>%LP(# @-C$R(#<Y,ETO365D:6%";WA;
M," P(#8Q,B W.3)=+U!A<F5N=" Q.2 P(%(O4F5S;W5R8V5S/#PO1F]N=#P\
M+T8Q(#(Y(# @4CX^/CXO4F]T871E(# O5'EP92]086=E/CX-96YD;V)J#3@@
M,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:" Q.3@W/CYS=')E
M86T-"GB<U5E=;^.X%7WWK^#;9H%8U;=D]&F;W2RRZ+3928HMBK[0$F6SD"4-
M*<7CO]%?D)_:<TG)EBUY=F?R4&0&,Q 9DI>\/.?<>YE/"X_1WX\_+UPG9?M%
MO&))X++=PO<3)_!-HUP\+5SV\^S0=#PT'0W=SPWW? P/O,A9Q:;QA95]=S34
M=W]GY7@58KB7A+01:GQA9=<_#:7&E96C '_ZU=/ P3=F!2LGCH?VC(VS2:D3
M)^-)ICVV]NOBT^(OSV93D<^><_Q@Z:7T\:=[+(FNHE]<;18W[%XJW?Z-[P3[
M*[<?]Z+:L']MZ^[[Y_]@\F8\>NARF7NV]&C(7;WC#:\.C-:ZV\J*LZ=_/K/'
M+5<[GHFNE1DO]2U[J#+GVRS\TE6">?$M\UTO88]\(UCTQU;R!S>DO^N%B]D_
M/<.Q<*O'J,,#>E@2!NQY-_+JS9GGQB/]E$;>_ %OC&=Y9OV;'T4F=FNA6.#:
M(U^,BU=V]9,CL-E/!@<^^\7@8OCWZY5^^[/1\3P7N&)QXCM1=''(1M69T/K?
MW]\R7N4LESHK:RU8NQ5,?&Y$UHJ</J3BK:PKEO-6L+I@NLNVK$&C:IDLV$;Q
M"B.=;]KO_Z_?=9(()".WAXD3D5 %KH,;L$TB(I'P'"EQN"(G3GL K6SLVSNA
M6ED $JW0QKN/0NUD"WPTYG+#\=4?#9^66GI12GT#9*^=8KP]Z N+@\CQ+^[Y
MBQ<S709G\ETGOD2+'P\W/$77W/C'4G" *2NYDL6![;<"N%(&7,T99]B.5UW!
ML[93$JQKC*.8U&:H)B9S\SWV6&_7C1W?V+WY('*92:C)HZKS+C-XM2YG2A1"
MB2H#F-%IW!\[K^\6K5'J.29$Q2F%*-N<1VN4^DYR@==CWR5B/XI-5QJB#Q@]
MDZ>CN?'TY2JFSJ\%:82U5F\%:10A1$] FEP%Z>SX'J00N9++"B ]6/4K"JB?
M)K%[OOOPR!H+*C!9"29W3:VU7)=0RIJM\;_0I)19*2O"<WF8(C5"D%]9I)(8
MD(TUU\!X42N6BY:06A'Z!YKPP2810?-"&!&Q^Y(OPLR#G# )Z:UR6.^TT.]+
M@F<OU0L=;W*IZ?5+G1M_NE3K:_*@L)* "Z,PUVFK+HV2&22JKEI5EZSD>ZO5
MZD@%S:JZ/0G']&+#U8J821?K)<[KZT-E#6()KG(PR>[E++8>T=1N>6L@!2.X
MT0ZF)<T7KX@;O*PWKW4Q8S*->B#?[$CU^HT>%U-"[M:=TIP0BC5[T7W\>/=?
M.*+.)"175KI#V,[,9A# =W3N&5.@:P_;3QVB/ FY.4&MC#O!#R5>1-51D&M;
M)===RWMB8)P^G16N>5?@'"MN&*+,,)EZ2&'.-N<5-T3N$%XH[K'O4G$_\ J8
MVB&-.O/\8&4\:QG[U#D([6AOMAIS32$4]M78S+X"SXDN]S7T7>[KI\\BZXS*
M_+U "B/4D+7$WEG6,A@=+[/T@H!ZOS8DA&!/\M:0$+K!C'JLKJK'[/A>/7*A
M,^#9,G;=:>06$(VBJS)+-Z0IT& 0D*T/[(-R3+5 F<H+2<K.7*UB<_P-4.GU
MDO'4?29:\6KCL!]*75^Q"IH940%29'MPV$/!;(;$*\9Q1:7L,W.:!>61NJ6<
M_';&=C($P1M8TRWF@9G]D3GM8%#-FJC[(G-Q/-QWFO2RRF0# :FSK&ML68!(
M)'9-61\F2+8FHV/HHZ!EY .5&2L(8 ?!E7['R5@ LI(T^%%$B9!MSE,P".*)
M-!S[+BGX6'*CKC_259*JDJ/I7OY!>KY7LD6R<$;&80/C!5%P!^/\;+1OSP@:
MKB8.3>/*GGUW(AO'OLL]_\85H6X0BY5[AH7>U-GD99I0Y]=J18"T_\U:X:_\
M*?=1AUW3BMGQOYG0;=EJR$04L)&8NO:]1_H\46K=B;R/C38RTTU2MJ<&WJ)2
MR:$B4QKY23*H1L-5.[#]'AK$[I?>G]FVWB,4J]MSRWEMD@O>-&!:OX^1)9MN
ML$+@#!2X9^S&P: 88.\Q&^KS&$VO!)U&"@73]MXA@=T(I/C1KA&5-EKAL%YJ
MD#5(FPW-6 S303"&M V6^T\CAH>Z4XQD#\OC9*J&+L'YY>%])<!C(?']P.88
MB4^,M<UY4OI^-!&28]\E*9_DIN*HK,5 2\\]Y^5@+SK3#=?]EKK.]SS<WQN)
MZ:T2QYT0T[M*S-GQ#P/D;9Y?]WD,TW"'L/57CQ^@:RVVO"QFXB<B8HO M]G.
M ]5+_?[9X^8T"5&RHC>+O!9Z1+T)\NO9EY'3.FP[IP)4A?<O'I.C.*]L',@1
MJ<LN[RL.KCBR_&9K#BD^4[51EO6>''!N]KLYHU'@I">C!D[@(RVBVBUIR*!"
MM_VZ-BLRJGC$W^!?)$Z:>%Q*4S7+:L8@JN70&GRHL*_^/<>[?;5Z)5'[5KE$
M=M(A%<EXPS-HC7C/B82'0I9^1^&GL;-:]<UY_GOT6X\+_A_[)N^0<'5=2GJZ
MS=F]K%#S4?WW- 2K01;NE\%9.C%L8[SLTL>NT/NULN"Y")UOE06D"I,'[,"_
MJ@ISPX=H;<)'7Y%;9-KJ7K,PNF619Q*MR.]K>.*(#3AUUNDA]F$:6)UMI^!-
MAIK"O/3DB,EEW9B\  2HQ)[]D+]P\QIY]K1DX[;NUL@CD.;CCF "9C-L"^9I
M(>R]/^[_ +0VQ)<-"F5N9'-T<F5A;0UE;F1O8FH-.2 P(&]B:@T\/"]#;VYT
M96YT<R Q," P(%(O0W)O<$)O>%LP(# @-C$R(#<Y,ETO365D:6%";WA;," P
M(#8Q,B W.3)=+U!A<F5N=" Q.2 P(%(O4F5S;W5R8V5S/#PO1F]N=#P\+T8Q
M(#(Y(# @4CX^/CXO4F]T871E(# O5'EP92]086=E/CX-96YD;V)J#3$P(# @
M;V)J#3P\+T9I;'1E<B]&;&%T941E8V]D92],96YG=&@@,C X-SX^<W1R96%M
M#0IXG-586X_;MA)^]Z\@ IQB"WA54;(DNV^YG T2I,VV6;1IT1>N1-ML)=%+
M27;<O]%SWO-3SS>D),NVG.WEX2";7<2DAW/CS#<S?)AP1O^^?SGQO3G;3>(%
M2T*?%9,@2+PPL(M\\F[BLY>CI/,AZ7Q NALCYP'(0QYYB]@N/L$Y\ >D@?\(
MYW@Q SE/9J0(+3[!V0\.I+2XP#D*\=-RGX<>/N-4N/#BN%N/R#@Z-/?B9'C(
MKH?2OIL\3)[=6:6B@-UE^.*:S^G#5S=@B:UER]RL)E?L1IFJ_E84DKT1[L.-
M+%?LY[5NOKS[%8=70^INRV?^$>L!R7-=B(TH]XQX/5^K4K!W[^_8[5J80J2R
MJ54J\FK*7I6I]_<DO&Y*R7@\98'/$W8K5I+%?XY3T+EA_J@73D[_^PZ.A5LY
MHPV.Z&')+&1WQ<"K5T>>&U(&<Z*\^A/>&)[BEO_5"YG*XEX:%OK.Y!.Z>.&X
M'QP!91]L' 3LM8V+[N^["_ONNX%YW$=<L3@)O"@Z,;+6S,A*"I.NF2@SELFM
MS/6FD&7-])*5<L<V1F=-6E?V^[UN#*O4A\-NVA@#ZGS/5,GJM1S:TPJ.YAZW
M@J\NRJIJV.NQEVHK+9=*LDQ5::ZK!F>F;)-+@;U:YCEK*K9;[TD5EFE6ZGI$
MY"ST$B>RDAMA! [NV4,CREHM]Y=-EA\VLJQDQ73I3%5EJA%'4*^6SBEF1%JP
M\$(GC91NJHIMI%$Z8WJ+FVX_IVM1KL!:M:R_>?'%4^\C>YIEJE:Z%'F^GQY4
M7&H#0T=D\9FW>,29O17W^^Z>6 HBE<$*RUD*'&OUVA"?LI89\1D1Z/MMV%P=
MO"\-?-*0Z$(W)<4&-HQ,M<G I[,PU66E<RLU8TMD2YDJD1^<67E_*[[_?_L^
M!=5N@C2-DLB+J+#%@8>,=4L";@+M8V2)DH2\=[X#*$J'N<@]]M:L1*E^%Q00
M]EIO#2)0;>"UIVFMMH@4>104O?P#QVN^\&FO0[J!TA'*#"D]][VX6UY0.N8>
M/U6[VSM5_'M9U09!UD#9E57[W9H"XE55(9Q3B?0E-+NYCH]4;[4XXGH=4- %
MO?*7;F*H+>*313,T&"?8]LG@.F<#5<*@18T!ES#LHO0,44?I;QU2&;E5^(^<
MD>;"4$K;G!B@&G!.U.S)N^8#)3W @>U$91'';+2Q28,HL/5Q,3U/S(C/.]0)
M?#^:(BT5,I)XI#K/)<4+H1ZRL#:TD1$>O%:BW*BVLDWM\A[Y2BNK['O5+*'*
MB#@_[(#G)^B+6"W9-V+/YJZ,30FU\6<DD(%N?ZWS3!H8:419+26*!  &^&&_
MQ+9F!\//I<WFBPYUAMS(2&W!9BD*!>,*6TPKJE7C\KTG[&ZMX-:**H6%)%75
M )\1F4CBMD[M5+T^NBIMJQ*KJ*FPP>SN[BW=#]28=4[82?Q"O:-;O%089['?
M5:EG!JE=K=D/RJQ _JK*<1D6P%6;1&0B]Z>A[T]]WX<A10&EJEJGOP%^:^9[
MOL^AFV%;D3=04(\(G,5=R/RL'IJR#8(7ZG#_?=>#RRUAJ"TH;U2A8(CS?JU7
M$N881AX&8_]?(X)"W@5+>]_0?A#HOUS],5@-[^L_OWSI/?FLRL(8DLS\N VE
M(9+,+B+)*/TQDIRAAZV_-@PIK=H$N&\J54HT(+@V6RQ8B9#-;,I\*O;#!>]"
M$3FDFQ4BH+8<ERH'7'CLAMJ&#Z) )^9R'>GD\I@6CY9Z9-"(U"3IXK&K$ @&
MO;.PM*J:8<@<-]D83+PI>U/;IH7="?4[A2S(+P%*2(6RS34%S=-UJ7.]VA,C
MXN.YKD94UIQ,B941!:4]*?;QYCJQBE4#S=A[J ;1H])F\PZ^+NCMG2A^X,;.
M]','1DI B) Z=-:;#O(_K[9J+']"OZMMP_R)+N;/*/U;0DV:$M9B2Y68H4U1
MA:NK2U0DJH(;HPA:#3/4G/=S!CKH7!!L:^IW*2+WQW.@$QLL^IJ8R5J: KF7
MN:P1J@/B-C.'@,V:$EB7[TD#F]?RH5'U >O=K#5:,X*D+XP4K4@[V]#3B)XI
MLDK:\_>RWDDW2E%?3B!.VMC&TH)QVZ /=(+EF1H+YB#NZV*SZ1+^U>W;3LF+
M?L5TXVIO"14+U]3N%,!J+?,-7)0"6@@@&'09$1OUU9$@$)-HI[9(4YHZ2(X=
M9DZ=A^*;-V1+:QG,I(&H[ZI'9(5]8;R7I5PJBUX -<QO%9U:2E$3ZGY>J36<
M6 +./7J@"A8+>IERR_'F/^"!-S]I_ON]T^8_\(!>12',WM9XM2H5W <8QL32
M7],M:D-Z.KITB@P97]N7PG!D>.&+R*,7O  P$"?M<EQ_OHB]Q8G^_=ZI_L\$
MBB*I_KPO8;CP?F3A_$CG3OB0V36/0]K]JS,+GX=N\ODG,PN/Y^>O.HCF2T@Y
M2O\3/:6XUD+:C-YB8M%-V[R+U*&&*K<ZW_;]+'ML[#M/,Q[U]:JMK%3R 1-M
MJ[,Q>JLR:=\8J .W2(K11>](P@!&ON[]U#_[M1)<X458>4$$Y)LLK2?/J&:(
MN9#91Z*>Z"^\I7%X.#YQXG]'7!Y$WGR<^D?70+F7&%<BR/=#?^O4OJVAQ5FB
MMJ ?I[>>D _G+?N@XTX?>;N5&\ +UMN%KNJN#HQV9PXR!V\W;=L'!&\??>SN
M/27+] "P8T+]Q.4S4+LM1U0SJ#LA8!B"-]!?&HNK4U?$$#@%?4& G4L+US#N
MR$4C$E&$9ZYS'7J/XO&D4(!! 2]@&A;=<$P#M^6\/[@;4I^B?N6,3T>D)8MV
MY.:1]_%2&":!%T<G ?8_*<.]00T*96YD<W1R96%M#65N9&]B:@TQ,2 P(&]B
M:@T\/"]#;VYT96YT<R Q,B P(%(O0W)O<$)O>%LP(# @-C$R(#<Y,ETO365D
M:6%";WA;," P(#8Q,B W.3)=+U!A<F5N=" Q.2 P(%(O4F5S;W5R8V5S/#PO
M1F]N=#P\+T8Q(#(Y(# @4CX^/CXO4F]T871E(# O5'EP92]086=E/CX-96YD
M;V)J#3$R(# @;V)J#3P\+T9I;'1E<B]&;&%T941E8V]D92],96YG=&@@,3DS
M,SX^<W1R96%M#0IXG-5837/C-A*]ZU?T4:FRN?PFM7O*3L93D]HDCNW*?M1<
M( J2L$42&H*41G\C57OW3\UKD)0HFIIQ,H>MV&67 #70C4;W>]WX./.(?Q_>
MS5PGI<,L7E 2N%3,?#]Q M\.\MGCS*5WDZ+I4#0=B!ZFQ#T?XH$7.8O8#CZS
ML^\.1'WW"SO'BQ#B7A*R(3SXS,ZN?Q;EP96=HP _W>YIX. S5@4+)X[[\82.
MBT6I$R?#178\U/;S[./L[T_6J,BGIQ6^N/52_O"7.VR)J76W>;69S>E.5:;^
M4122_B':#W>RW-!_MKKYYNF_6+P92O=3+KD76P]$WNA"[$1Y)-[KS5:5@A[_
M]43W6U$5(I--K3*1FQMZ7V;.']/P?5-*\N(;\ETOH7NQD92\;B>_=T/Z12^,
M5K]]@F/A5H]XPD/T4!(&]%0,O#J_\-Q0TD]9<OX*;PQ7>7;_^7<RD\525A2X
M[9%'<O&BW?WL"!C[T<:!3]_;N.C_?KXR_^7O!D?W7,0<Q8CU='3^_W7*A\)^
MY*33TF]TN59508>MK+<X'O[1&@XJ,R5R,K6H92'+VI PM*NDP6>Y(E5F>;.2
ME.G2Z%RM1*UT27H]=$JO-':=T+KFL?G4B+(6Y>;&JOGE_5O2>^@\;%6VM5.9
M+FS4ZF4M5 E%4%!7.J>]$OV:*1UA;#5\NZFD-9?8S,H:6FN":3]EM>;;\X+V
M]IQG>K\FHV&)S'-J#!UU4]%2&(4X:(^GRLV4KL!S6FV57$-'F4F"#K.3F5JK
MC$26Z::LL9AR!2-$W53RAM:Z&GH+WYH&AV8?["J%+[$'#CBE$-;Z5B$62CCY
MY+S3<9U3O)VRJ8L/CXT-R'?\B"HY6]O@&@NYB9-&D J<9"#U.\(P6@ 'HU?'
MX:3X?:7W"B&%JQ"T4F)3B8)4GC>FKEJ'V1O*=+73%3L"\TW&SCT[D,,GEUTL
M7G%GE$;L#/;G@^SWX.U%N:)'((*D]\8@4#/I/#]/G*$]<>(YX?@(SW\H[?]_
M\R[?]V$&](K"V&&:]0/+9.V0^8RY[!)PHS!Q%GSPJ3F@=#9"ER[BD8MW)UAY
M/,'*\().RH>;W7IQS+,]_@]L#D#*;#.B"<S<#J_8'/ACB]N9L;V^0X]-48CJ
MR 'TJ#8EYS1 B[X]I_4]3I0I>6E[;\1YVUM;/ 53EGLA0@B6AR'70.WPBN5>
M['ACV_NYL?4?YML/W_26&GH 9:F]6.: GQW3TAVX]\+H7O]POULO\7FV-_M:
M\ SM9,]'KN^,J?BS^?!R&Y_"-&$O7>X2),ZU-)R4_[=N " FR[4!-&]%33^(
M$N>WQ%#)O9('8S%4K.3'1F3''E-%GNL#)[Y%ZY5NEO6ZR2\PI-6:H$AL(43T
MS@;D"*!.N=$<(AV/-(8'6V5J77&) 8#*<YE9@*I!'2MC44=L6 Q&5*<;,Q-:
MH]19=%IY$>,D"+G):UZJ8$-[MALJ]96CT,G<@V!Q@.D*B<DB8-T)E0B0J%6Y
MDP#9U;D$ ('>-167##<,S&>'GU2<#T,,JJM&LI-6LH#U6'V?2V'DA$[DL=?I
M/%/"0=5MA;#6?#+VERIA=]%6'J;9@17.++&28-X">-.ZFF.@U!.ZT(0DG4M/
M#E.&2IAN#%#@K]>(-?2LE5]@UM!E'/T*8@T6:<O]K^+5*>FWGW8Y2BG46$=:
MB>.OAHQ >)%N:A1W)1<Y]&'^W>-/0 Z<'$&:-;F%:_C,=R->U$:IMW"?VT$]
M0:L!&J>V OY!5"AL J_K#'CIQ53,4;OC+-C+_(AB:XV[J6U\,(6#[W4A*_,K
M+E@L%6JH(^:G-,:+KK#<B>/?6,^URPKBP'&_JL )HI!+I%=?Q)3XL, ISSEO
MXW4J:8S<"2YT\J--T$JVUX+)&N33GW>L.72[NF1>;U5U%N<MI, MO$AD&H8(
MI_)2YDKNI?U\0 6&2HO_=]@UI=2/V;^LU,+@D<R .7?HY>SM#M#-^=-62H'K
M<>/O+APT?#R8YNT ;!B->/LT-^;M=[)$GS BFD[!<,DMF!"3OY>9_31UDJ]E
M9A^]H_>"F=.KS#PIWV(^#7 ='_7:<!X @ DU_PZ]()ASKU""YS>$J-UM=:V[
M;RY OX_/E[CN1XL>UWM=JGQF^D"K8!M83%L,LB9TW0-3:&.Z7DU^$MQ+8!UH
M%LF2*Z83U(7GE<Z$XC#J*X/NK("VK@@YR.="'&DK]K;/;;OJ2FY$94$8Z6H(
M)T-ZBOS/E1]?^W<9:P&'+$K2Q;B[&OS\D]$$%[*R06#=.WP^8,[AVRS.=1^7
M(,P[:$@4HRO?L:WYLJRI4 ->/.=8$_K4:ZNMRU)157W!@_[3<,55<X5R8E0V
MHJ_&^KN^@:ZV-07>+XU].+A\,;%Z/62KU]665GQYM(9B[_5Z(MV0F_;%<SK!
MQX[U8M=YT;8.?A[X38.3X:'A*B&,7>O,,/8&H5K!%VB=6U*! V7.SQRP%0US
M%_:VG.J\5LN7APR[EF->JZ*]#&0BU+9.L_X3\-K*WMWP@:17CAR6ZW5;1=#P
M801FJO;)0)<O]09>"X7ST\O6%9=ZR8L O.92-VS/<L6E$V\(4+!P7WME2?S9
M&^NW_PW732] #0IE;F1S=')E86T-96YD;V)J#3$S(# @;V)J#3P\+T-O;G1E
M;G1S(#$T(# @4B]#<F]P0F]X6S @," V,3(@-SDR72]-961I84)O>%LP(# @
M-C$R(#<Y,ETO4&%R96YT(#$Y(# @4B]297-O=7)C97,\/"]&;VYT/#PO1C$@
M,CD@,"!2/CX^/B]2;W1A=&4@,"]4>7!E+U!A9V4^/@UE;F1O8FH-,30@,"!O
M8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:" V-38^/G-T<F5A;0T*
M>)R=5-MRFS 0?><K]JGCSB0J2$C@/CJW-M.F2<-,+V\JE@T=D&(AXO'?^%.[
M&-, <2XM##.LM.><U5E)*R^ YOUZX?DDAK4GIL#CD$PYE!ZE$6&TBPOOUO/A
MXA!@2H> -GX K ^!A&A!+.!D*KKX&94H' *B\!4J8=R" LQN2FOC9U2X& *X
M>$:%,WSV0!83&C= -B5"=/$!I3XH9$30'JB-^VHWWLJ;)4URQ"DD<YPX#D).
M?-X%<?/S[ASY<7ZQ5[)+;P+GN:W<E2P5?)+MS[G22_B9F?IM\AO!RWYV-^2#
M/Z#NI9R84MY)O8&&ZR3+M83;[PE<9]*6,E6URU-95$?P4:?D_Q0N:ZT@$$=
M_2"":[E4$+^.B78VQ"^Z\!1Z'Y\EZ#IZ'D S$$!$(0H9)&7/Y<G R7XF-ATS
M)Z]PIX\*=OR34Y6J\I>RP/S6@E&>F+;L#\9@L:O=)J%PN=LTW7?SQ/B_?F,K
M!!Z,>&3&OI!^(B,<A A&B=O>\\/44,H-I$8[F3HXR6Q>N1S[GQBKU68K'5I
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6=&%R='AR968-"C$Q-@T*)25%3T8-"@$!

end
</PDF>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                             December 30, 2017

Feng Zhou
Chief Executive Officer
China SXT Pharmaceuticals, Inc.
178 Taidong Rd North, Taizhou
Jiangsu, China

       Re: China SXT Pharmaceuticals, Inc.
           Registration Statement on Form F-1
           Filed December 4, 2017
           File No. 333-221899

Dear Mr. Zhou:

       We have reviewed your registration statement and have the following
comments. In
some of our comments, we may ask you to provide us with information so we may
better
understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Registration Statement on Form F-1

Cover Page

1.     Please revise the description of the escrow arrangement to clarify
whether any funds will
       be promptly returned if the minimum offering amount is not sold. Refer
to Exchange Act
       Rule 10b-9.

2.     Please revise to limit the prospectus cover to a single page. Refer to
Item 501(b) of
       Regulation S-K.
 Feng Zhou
FirstName LastNameFeng Zhou
China SXT Pharmaceuticals, Inc.
Comapany30, 2017
December NameChina SXT Pharmaceuticals, Inc.
June 16, 2017 Page 2
Page 2
FirstName LastName
Our Competitive Advantages, page 6

3.       Please provide the basis for the statement that Suxuangtang is a
well-known TCM brand
         in China and that the curative effects your products have been proven.

4.       Please advise whether any additional permits or certificates are
necessary to market your
         products throughout China. We note that you reference two regulatory
bodies, Jiangsu
         Food and Drug Commission and the Chinese Food and Drug Commission.
Please tell us
         how the regulatory authority of these entities apply to the Company.

5.       Please balance the disclosure regarding the experience of your
management team with
         disclosure that the CEO has relatively little industry experience.
Prospectus Summary
Overview, page 6

6.       We note your inclusion of a glossary on page 5 to define certain terms
used throughout
         the prospectus. Please also define the TCMP concept in the Overview
section as well as a
         brief description of the traditional Chinese medicine industry in
China and the key
         differences from the regulated pharmaceutical industry.

7.       Please provide the percentage of your total revenues that are
attributable to Advanced
         TCMP, Fine TCMP and Regular TCMP and the number of products currently
marketed
         in each category.

8.       Please disclose the indications for which each for the products
disclosed in the first
         paragraph are used and when you commercialized each product.
Our Growth Strategies, page 7

9.       We note your statement that you plan to promote the efficacy and
safety profile of your
         established prescription Chinese medical products. Please clarify
which of your products
         this statement relates, the entity that establishes the efficacy and
safety profile of your
         products and any needed regulatory authority within China to state
claims about the
         efficacy and safety of your products.

10.      We note your statement that you are conducting clinical trials for new
generic or
         modernized Chinese medicine products. Please clarify whether these
products are
         TCMPs and if they are material to your Company please clarify the
stage of clinical trials
         for each product. We note disclosure on page 57 that Chinese
Traditional Medicine is not
         required to go through clinical trials before commercial launch.
Please also clarify the
         reference to "modernized" Chinese medicine products.
 Feng Zhou
FirstName LastNameFeng Zhou
China SXT Pharmaceuticals, Inc.
Comapany30, 2017
December NameChina SXT Pharmaceuticals, Inc.
June 16, 2017 Page 3
Page 3
FirstName LastName
Implications of Our Being an "Emerging Growth Company", page 8

11.      Please supplementally provide us with copies of all written
communications, as defined
         in Rule 405 under the Securities Act, that you, or anyone authorized
to do so on your
         behalf, present to potential investors in reliance on Section 5(d) of
the Securities Act,
         whether or not they retain copies of the communications.
Our Corporate Structure, page 8

12.      The charts on pages 8 and 46 do not match the chart on page F-7 with
respect to the
         identification of the entities above and below the dotted line as
either "On Shore" or "Off
         Shore." Please revise.
Risk Factors, page 13

13.      Based on the disclosure on page F-19, it appears there are three
customers that each
         accounted for more than 10% of your total sales. Please include
appropriate risk factor
         disclosure regarding the concentration of you sales to a small number
of customers.
Our pharmaceutical business is subject to inherent risks..., page 16

14.      The risk factor refers to your pharmaceutical business and the risks
that pharmacies are
         exposed to, which does not appear to apply to your business. Please
revise the risk factor
         to reflect the business in which you are engaged, or advise.
Enforceability of Civil Liabilities, page 32

15.      We note your statements that you have been advised by your counsel
with respect to
         certain British Virgin Islands and People's Republic of China law
matters. Please tell us
         what consideration you gave to filing the written consent of your BVI
and PRC counsel
         with respect to these statements as an exhibit to the registration
statement. See
         Rule 436 under the Securities Act of 1933.
Use of Proceeds, page 33

16.      Please specify the new drug candidates that you will research and
develop with proceeds
         from the offering. Also disclose the stage of development you expect
to reach using
         offering proceeds for each of the candidates you specify.

17.      If any additional funds will be needed to accomplish the goals listed
in the table, please
         revise this section to discuss the sources and amounts of those
additional proceeds.
 Feng Zhou
FirstName LastNameFeng Zhou
China SXT Pharmaceuticals, Inc.
Comapany30, 2017
December NameChina SXT Pharmaceuticals, Inc.
June 16, 2017 Page 4
Page 4
FirstName LastName
Management's Discussion and Analysis of Financial Condition and Results of
Operations
Overview, page 37

18.      Please describe the Chinese hospital market that you refer to in the
fifth paragraph and
         how your products are used in this market.
Industry, page 43

19.      Please explain the differences between the pharmaceutical industry and
TCMP industry
         in China. Please provide the basis for the growth rates associated
with the TCMP
         industry.
The Future of Directly-Oral-TCMP and After-Soaking-Oral-TCMP Markets, page 43

20.      We note your statement that Directly-Oral-TCMP and
After-Soaking-Oral-TCMP have a
         strong probability of dominating the TCMP market in the coming years
and potentially
         generating large profit for you. Please discuss the assumptions on
which the statement is
         based and balance the disclosure with the potential competition you
face in these
         markets. Alternatively, please delete the statement.
Business, page 44

21.      Please identify the entity that awarded the Jiangsu Taizhou Famous
Product award.
Our Corporate History and Structure, page 45

22.      Please expand this section to discuss how your business evolved over
the past five years.
         We note your disclosure on page 13 that you became principally engaged
in offering your
         principal products only two years ago. Refer to Item 4 of Form F-1 and
Item 4.A.4 of
         Form 20-F.
Share Pledge Agreement, page 47

23.      Please quantify the full amount of fees payable by Taizhou Suxuantang
under the Share
         Pledge Agreement that will enable the termination of the agreement.
Research and Development, page 51

24.      Please specify the international manufacturing standards that you have
adopted and
         jurisdictions in which you have applied for the patents referred to in
the first paragraph.
Intellectual Property, page 53

25.      For each patent application you have submitted, please disclose the
type of patent
         protection you are seeking under the application (e.g., composition of
matter, use or
 Feng Zhou
FirstName LastNameFeng Zhou
China SXT Pharmaceuticals, Inc.
Comapany30, 2017
December NameChina SXT Pharmaceuticals, Inc.
June 16, 2017 Page 5
Page 5
FirstName LastName
         process), and disclose the expected expiration date of such patent if
granted.
Certificates and Permits, page 54

26.      Please clarify whether the pharmaceutical manufacturing permit is the
same as the
         Medicine Production Permit referenced on page 6.
Regulation, page 57

27.      Please explain why the effects of TCMP products are impossible to be
tested clinically
         and the basis for determining whether a product is safe and effective
for its intended uses.

28.      Please expand this section to discuss the price control laws and
regulations noted on page
         17. In this regard, please disclose the products that are not found in
the catalog of
         medications that are reimbursable under the PRC's social insurance
program and
         quantify the portion of revenues attributable to these products.
Management
Executive Officers, page 61

29.      Please describe the business functions performed by Mr. Zhou as vice
manager of
         Suxuantang. Also describe the business of this entity. If it is an
affiliate of the registrant,
         so state. Please also expand to provide Mr. Zhou's principal
occupation or employment
         for the past five years.
Plan of Distribution and Underwriting
Warrants, page 90

30.      We note the statement that the warrants to be issued to the
underwriter are registered as
         part of the Form F-1; however, the warrants do not appear to be
registered in the fee table
         or noted on the prospectus cover page as underwriting compensation.
Please revise the
         section or sections of your filing appropriately.
Signatures, page 100

31.      It appears the officers signed the filing on behalf of the registrant,
although the
         registrant's name does not appear. Please revise to clarify whether
the registrant has
         signed the filing. Please also include the paragraph of text following
the registrant's
         signature set forth in Form F-1, followed by the signatures of the
persons listed in
         Instruction 1, in their individual capacities.
Consolidated Financial Statements, page F-3

32.      We note your disclosures on pages 45, 51 and 52 regarding your focus
on the research
         and development of new Advanced TCMP products, the substantial
resources you devote
 Feng Zhou
FirstName LastNameFeng Zhou
China SXT Pharmaceuticals, Inc.
Comapany30, 2017
December NameChina SXT Pharmaceuticals, Inc.
June 16, 2017 Page 6
Page 6
FirstName LastName
         to research and development of new products and your six products
currently in the
         research and development stage. Given these disclosures, please tell
us why you do not
         separately quantify research and development expenses on your income
statement or
         discuss period over period changes in your MD&A. Additionally,
quantify for us
         research and development expenses by product candidate for each period
presented and
         tell us where such amounts are recorded in your consolidated financial
statements.
1. Organization and Principal Activities
Restructuring and Share Issuance, page F-6

33.      Please revise and clarify your disclosures that "Suxuantang was
incorporated on June 9,
         2005, which was collectively controlled by Jianping Zhou, Jianbin Zhou
and Xiufang
         Yuan. On May 8, 2017, the three shareholders transferred all shares to
Suxuantang
         shareholders, who are family members of the three shareholders." This
is not consistent
         with disclosures on the same page that "On July 4, 2017, we were
incorporated in the
         British Virgin Islands by issuance of 10,300,000 common stocks at
0.001 par value to
         Ziqun Zhou, Di Zhou and Feng Zhou Management Limited, who together
hold 100%
         shares of Suxuantang ("Suxuantang shareholders")."

34.      Please revise your disclosures such that all of the business entities
named are consistent
         throughout the filing. For example, the notes to the consolidated
financial statements on
         page F-6 show Jiangsu Suxuantang Pharmaceutical Co., Ltd and Taizhou
Suxantang
         Biotechnology Co. Ltd. whereas the diagram on page F-7 shows Jiangsu
Su Xuan Tang
         Pharmaceutical Co., Ltd. and Taizhou Su Xuan Tang Biotechnology Co.,
Ltd.,
         respectively.

35.      Once you have an estimated offering price or range, please explain to
us how you
         determined the fair value of the common stock underlying your equity
issuances and the
         reasons for any differences between the recent valuations of your
common stock leading
         up to the IPO and the estimated offering price. This information will
help facilitate our
         review of your accounting for equity issuances including stock
compensation and
         beneficial conversion features.
2. Summary of Significant Accounting Policies
Basis of Consolidation, page F-11

36.      You disclose the various transactions involved in the Restructuring
and Share Issuance
         on page F-6. Please provide us with the following information:
           We note each of these transactions occurred after March 31, 2017,
the date of the
            most recent financial statements included in your filing. Tell us
your basis, including
            reference to specific accounting literature, for assuming
completion of each of these
            transactions and accounting for them retroactively as if they
occurred on April 1,
            2015.
 Feng Zhou
FirstName LastNameFeng Zhou
China SXT Pharmaceuticals, Inc.
Comapany30, 2017
December NameChina SXT Pharmaceuticals, Inc.
June 16, 2017 Page 7
Page 7
FirstName LastName
              Confirm whether the financial statements as presented include
consolidation of
              Suxuantang, the VIE over which the company obtained control via
the VIE
              Agreement entered into on October 13, 2017. If so, tell us your
basis, including
              reference to specific accounting literature, for consolidating
such VIE prior to the
              date of the VIE Agreement.
              Provide us a diagram illustrating your corporate structure prior
to completion of the
              Restructuring and Share Issuance.


Consolidated Financial Statements
2. Summary of Significant Accounting Policies
(h) Accounts Receivable, page F-12

37.      You disclose that Management reviews the adequacy of the allowance for
doubtful
         accounts on an ongoing basis, using historical collection trends and
aging of receivables
         and as a result of its review, no allowance for doubtful accounts was
recorded for any
         period presented. Further, you disclose accounts receivable are due on
demand. Please
         provide us with the following information supporting your
determination that no
         allowance is necessary:
           Explain why day's sales outstanding (DSO) is calculated at 205 days
and 190 days at
             March 31, 2017 and March 31, 2016 respectively, if not due to
customers' inability to
             pay; and
           Provide us an aging of your accounts receivable separately for
related parties and
             third parties for each period presented. Explain why you believe
you will still collect
             on any significant past due receivables.
General

38.      Please provide us proofs of all graphics, visual, or photographic
information you will
         provide in the printed prospectus prior to its use, for example in a
preliminary prospectus.
         Please note that we may have comments regarding this material.

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.
 Feng Zhou
China SXT Pharmaceuticals, Inc.
December 30, 2017
Page 8


       You may contact Christine Torney at 202-551-3652 or Sharon Blume at
202-551-3474 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Chris Edwards at 202-551-6761 or Mary Beth Breslin at 202-551-3625 with
any other
questions.

FirstName LastNameFeng Zhou                               Division of
Corporation Finance
Comapany NameChina SXT Pharmaceuticals, Inc.              Office of Healthcare
& Insurance
June 16, 2017 Page 8
cc: Joan Wu
FirstName LastName
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
